Survey exploring access to Standards of Care for people with Spinal Muscular Atrophy (SMA)

As part of a PhD project, the John Walton Muscular Dystrophy Research Centre in Newcastle are conducting a survey to explore access to Standards of Care for people with Spinal Muscular Atrophy (SMA).

They have asked us to spread the word within the SMA community, they would also like to make it clear that only one survey per patient is filled in, this can be by the patient, or by a relative or carer on behalf of the patient.

They are also conscious that due to the current situation with COVID patients’ regular routines might have changed substantially. If this is the case, respond to the survey reflecting their usual life before the outbreak.

You can complete the survey following the link below:

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more